Abstract:As the most potent antigen-presenting cells, Dendritic cells (DCs), capable of inducing immune responses from naive T cells, are operative tools for tumor immunotherapy. Derived DCs are extremely effective in capturing and presentation of antigens to T cells and play a key role in the induction of cytotoxic T lymphocytes (CTLs). In vitro culture system containing the combination of GM-CSF, IL-4 and TNF-α cytokine can affect CD14 + progenitor cells from mononuclear cells (MNCs) of peripheral blood (PB) developing into functional DCs, which have enough quantities for application in vitro researches and clinical practices. Multiple myeloma cells(MM)are able to secrete a great quantity of immunoglobulin (Ig) expressing idiotypic antigen called idiotype (Id) in its mutational hotspot. This kind of idiotypic structure regions also expressing on the surface of MM cells are high specific autologous tumor associated antigen (TAA). The combination use of DCs and tumor specific antigen can improve the immunogenicity of MM cells and stimulate specific anti-tumor immunological response effectively, so by using this new kind of DC tumor vaccine, following high dose chemical therapy, the tiny residual pathological changes might be cleared totally in the future. To investigate the specific antitumor immune response induced by Id-pulsed dendritic cells(DCs) in vitro. DCs were generated from peripheral blood monocytes of the multiple myeloma(MM) patients using GM-CSF, IL-4, and TNF-α. pulsed with idiotype protein at the immature stage, DCs could activate T cells to become tumor specific cytotoxic T lymphocytes (CTLs). The morphologic characteristics of those cells were observed with light and electron microscopes. The phenotypic figures were analyzed with FACS analysis. Methy-thiazoly-Tetrazolium (MTT) assay was employed to evaluate the effect of proliferation of autologous T cells and the inhibition rate of CTL on MM cells. DCs precursors in peripheral blood could be induced to typical mature DCs in medium containing GM-CSF, IL-4 and TNF-α. Mature DCs with Id could operatively increase proliferation of the autologous T cells and active naive T cells to become tumor specialized CTLs. Any doses of CTLs had significant inhibition or killing ability on autologous MM cells. These results suggest in suitable cytokine environment, the precursors in peripheral blood of MM patients could be induced to functional DCs, and vaccination with Id-pulsed DCs could induce active antitumor immune response. Multiple cycles of immunization using DC as APC in vitro can be beneficial in generating antigen- specific T cells from normal PBMC, and Id an auto-specific tumor antigen, can be got with ammonium sulfate four-step precipitated method, By digestion of pepsin and affinity chromatography so as to stimulate MM specific immunological responce, and Id-pulsed mature DCs from MM patients can stimulate not only the proliferation of autologous T cells, but also the specific CTL immune response against autologous MM cells. In addition, in vitro immunization may provide an alternative approach to in vivo immunization of MM. We believe that DCs vaccine can bring the breakthrough of therapy to MM in the near future.

Induction of Anti-Tumor Immunity by Lyophilized Myeloma Cells Secreting GM-CSF.

Genetically Modified Myeloma Cell Vaccine Inducing Antitumor Immune Response in Vivo.

Native Anti-Tumor Responses Elicited by Immunization with A Low Dose of Unmodified Live Tumor Cells

CpG or IFN-α Are More Potent Adjuvants Than GM-CSF to Promote Anti-Tumor Immunity Following Idiotype Vaccine in Multiple Myeloma

Eliciting Protective Immune Responses Against Murine Myeloma Challenge in Lymphopenia Mice Through Adoptive Transfer of Tumor Antigen-Specific Lymphocytes and Immunization of Tumor Vaccine Secreting Mil-21

Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro

Study of immunotherapy of murine myeloma by an IL-21-based tumor vaccine in BALB/C mice.

Antitumor effect of granulocyte-macrophage colony-stimulating factor (GM-CSF)-gene encoded vaccinia melanoma oncolysate and its immunological mechanisms

[The Anti-Tumor Activity of GM-CSF-modified Lung Cancer Cell Vaccine and Its Synergism in Combination with Chemotherapy].

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Enhanced Interferon-Gamma Secretion and Antitumor Activity of T-Lymphocytes Activated by Dendritic Cells Loaded with Glycoengineered Myeloma Antigens

Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model

Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a mixture melanoma model.

Anti-lymphoma immunity induced by EL-4 cells transfected with B7.1 or/and GM-CSF gene

Dendritic Cell Vaccines Are Superior to Idiotype-KLH Protein Vaccines at Priming a Therapeutic, Tumor-Specific Immunity Against Multiple Myeloma.

Active Specific Immunotherapy of Pulmonary Metastasis with Vaccinia Melanoma Oncolysate Prepared from Granulocyte/macrophage-Colony-stimulating-factor-gene-encoded Vaccinia Virus

Vaccination With Allogeneic Gm-Csf Gene-Modified Lung Cancer Cells: Antitumor Activity Comparing With That Induced By Autologous Vaccine

The Anti-Tumor Immune Responses Induced by a Fusion Protein of Ovarian Carcinoma Anti-Idiotypic Antibody 6b11scfv and Murine GM-CSF in BALB/c Mice

Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects

Anti-Myeloma Effects Induced by Myeloma Idiotype Pulsed Dendritic Cells in Vitro.

Microbial Antigens-Loaded Myeloma Cells Enhance Th2 Cell Proliferation and Myeloma Clonogenicity Via Th2–myeloma Cell Interaction